Dr. Reddy’s Laboratories recently terminated the trial study of Avigan in Kuwait


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Dr. Reddy’s Laboratories recently terminated the trial study of Avigan in Kuwait
"The full data analysis on 353 subjects would be available by the end of February 2021," said the company in a statement.

Hyderabad based Dr. Reddy’s Laboratories on Wednesday announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID-19 patients.

The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical program for Avigan, spanning the spectrum of Asymptomatic to severe cases of Covid in both outpatient and in-patient setting.

However, the company said that it will continue ten Phase-III studies in an ‘outpatient setting on patients with mild to moderate symptoms' in North America with its partner with Appili Therapeutics and Global Response Aid.

The data from the Kuwait CVD-04-CD-001 study involving moderate-severe Covid-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e. time to sustained hypoxia resolution) for Avigan vs. Placebo (7 days vs 8 days; p= >0.05).

"The full data analysis on 353 subjects would be available by the end of February 2021," said the company in a statement.

The subgroup analysis data during the initial interim analysis points towards the hypothesis with clinically significant insights that an antiviral drug like Avigan may be effective as part of early treatment initiation in coronavirus patients and not effective in the late-stage hospital treatment for moderate and severe coronavirus patients.

Avigan (favipiravir) drug is an antiviral influenza drug of Japan’s FUJIFILM Toyama Chemical Co., Ltd.

Story Source: https://www.indiatoday.in/india/story/coronavirus-dr-reddy-s-lab-terminates-trial-study-of-avigan-in-kuwait-1763397-2021-01-28 

Tags : #DrReddysLab #Kuwait #LatestCOVID-19News28thJan #AppiliTherapeutics #FUJIFILMToyamaChemical

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026